Loading...
Trial in progress: First-in-human study of a novel anti-NY-ESO-1-anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101)
Lopez, J Shinde, R Burgess, MA Sato, T Van Tine, B Rodon, JA Dukes, J Easton, R Marshall, S
Lopez, J
Shinde, R
Burgess, MA
Sato, T
Van Tine, B
Rodon, JA
Dukes, J
Easton, R
Marshall, S
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Lopez J, Shinde R, Burgess MA, Sato T, Thistlethwaite F, Van Tine B, et al. 1309TiP Trial in progress: First-in-human study of a novel anti-NY-ESO-1-anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumours (IMCnyeso-101). Annals of Oncology. 2019;30(Supplement_5):532.